Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a ...
HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to ...
The reduced monthly HAE attack rate was maintained for at least 1.5 years in the CHAPTER-1 OLE study. What improvements did participants report in the CHAPTER-1 OLE study? All participants ...
Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in ...
The findings were presented at the recent AAAAI/WAO Joint Congress and show sustained effectiveness in reducing HAE attacks and improving patients' quality of life. The CHAPTER-1 Open-Label ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results